Market Place
Sourcing Support
Pierre Fabre Laboratories Announce European Authorization For OBGEMSA
28 Jun 2024 //
PR NEWSWIRE
Pierre Fabre`s Obgemsa (vibegron) Receives Approval In Europe
27 Jun 2024 //
EMA
Pierre Fabre receives the Galien International Prize for EBVALLO®
21 Jun 2024 //
PRESS RELEASE
Sumitomo Pharma: FDA Accepts sNDA For Vibegron In OAB/BPH Men
13 May 2024 //
PR NEWSWIRE
Pierre Fabre: Positive CHMP Opinion for OBGEMSA™ in OAB
26 Apr 2024 //
PR NEWSWIRE
Sumitomo Announces Positive Results from Phase 3 Studies Evaluating Vibegron
11 Sep 2023 //
PR NEWSWIRE
Kyorin and Sumitomo to introduce drug for overactive bladder in Taiwan & other Asian countries
06 Mar 2023 //
PRESS RELEASE
Urovant Announces Publication of Pharmacokinetic Data on GEMTESA
27 Oct 2022 //
BUSINESSWIRE
Urovant and Pierre Fabre Sign Excl. License Agreement to Commercialize Vibegron
06 Jul 2022 //
BUSINESSWIRE
Urovant Sciences Publishes Review of Efficacy and Safety Data for GEMTESA 75 mg
22 Mar 2022 //
BUSINESSWIRE
Urovant to publish in Advances in Therapy of Improvement by GEMTESA in OAB
20 Dec 2021 //
BUSINESSWIRE
Urovant Sciences Presents Positive Ambulatory Blood Pressure Data of GEMTESA
13 Sep 2021 //
BUSINESSWIRE
Urovant Sciences and Sunovion Launch Primary Care Co-Promotion of GEMTESA
29 Jun 2021 //
BUSINESSWIRE
Altasciences Performs Phase I Studies for FDA Approval of Vibegron
23 Feb 2021 //
BUSINATSSWIRE
Vivek Ramaswamy`s `vant` brainchildren keep bearing fruit with Urovant`s FDA
24 Dec 2020 //
ENDPTS
Vivek Ramaswamy`s `vant` brainchildren keep bearing fruit with Urovant`s FDA
24 Dec 2020 //
ENDPTS
FDA clears Sumitovant`s Gemtesa for patients with overactive bladder
24 Dec 2020 //
GLOBENEWSWIRE
Urovant`s lead drug disappoints in mid-stage study first big FDA decision looms
26 Nov 2020 //
ENDPTS
Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron
24 Nov 2020 //
BUSINESSWIRE
Urovant Sciences Announces Topline Data from Phase 2a Study of VibegroN
24 Nov 2020 //
BUSINESSWIRE
Japanese drugmaker takes full control of a Roivant biotech
13 Nov 2020 //
BIOPHARMADIVE
Urovant Sciences Announces Co-Promotion Agreement for Vibegron SunovionPharma
08 Oct 2020 //
PRESS RELEASE
As Urovant preps vibegron launch, it’s all systems go on R&D
15 Aug 2020 //
FIERCE PHARMA
Urovant Sciences Announces U.S. FDA Acceptance of NDA for Vibegron
05 Mar 2020 //
BIOSPACE
Urovant Reports Positive Long-Term Data from the Double-Blind Extension
24 Sep 2019 //
BUSINESSWIRE
Urovant ramps up spending on Codexis ingredient ahead of commercial production
13 Aug 2019 //
IN-PHARMATECHNOLOGIST
Urovant claims a big win in PhIII — but questions linger about a cheap generic
18 Mar 2019 //
ENDPTS
Codexis signs enzyme supply agreement with Kyorin Pharma
11 Feb 2019 //
BIOSPECTRUM ASIA
Codexis & KYORIN Enter Supply Agreement
07 Feb 2019 //
CONTRACT PHARMA
Urovant Sciences Initiates Pt Enrollment in Ph2a Clinical Trial for Vibegron
03 Jan 2019 //
BUSINESSWIRE
Urovant Sc Completes Pt Enrollment in Ph 3 Trial of Vibegron-OAB
08 Nov 2018 //
BUSINESSWIRE
Urovant’s overactive bladder drug scores in mid-stage trial
01 Nov 2018 //
ENDPTS
Kyorin Receives Marketing Approval in Japan for "Beova® Tablets 50mg" for OAB
21 Sep 2018 //
PRESS RELEASE
Overactive bladder biotech Urovant Sciences sets terms for $150 million IPO
17 Sep 2018 //
NASDAQ
Urovant adds gene therapy to overactive bladder pipeline
28 Aug 2018 //
FIERCE BIOTECH
